bioAffinity Technologies, Inc.
Nasdaq · Healthcare · Services-Commercial Physical & Biological Research · San Antonio, TX
BIAF chart
What traders are saying about $BIAF
Latest postsbioAffinity Technologies, Inc. news
- bioAffinity Technologies expands Lung diagnostics pipeline into COPD and Asthma
Yahoo Finance ·
- bioAffinity Technologies, Inc. Estimates – NASDAQ:BIAFW
TradingView ·
- bioAffinity Technologies (BIAF) Edges Down 0.68% to $3.63, Testing Near-Term Support - Sentiment Shift
https://www.dars.gov.et/ ·
- bioAffinity Technologies to Present New Perspectives on CyPath® Lung’s Use for Cancer Risk Assessment at CHEST 2026
Yahoo Finance ·
- bioAffinity Technologies to Present Positive Research Data in Development of Its New Test Measuring Asthma and COPD-Related Lung Inflammation and Drug-Related Receptors at CHEST 2026
Yahoo Finance ·
- WallachBeth Capital Announces Closing of bioAffinity Technologies $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
Yahoo Finance ·
- bioAffinity Technologies, Inc. Announces Closing of $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
Yahoo Finance ·
- WallachBeth Capital Announces bioAffinity Technologies Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
Yahoo Finance ·
- bioAffinity Technologies, Inc. Announces Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
Yahoo Finance ·
- bioAffinity Technologies Receives Japanese Patent Allowance for CyPath Lung AI Diagnostic Test
investorshub.advfn.com ·
- bioAffinity Technologies Announces Notification of Japanese Patent Allowance Covering Noninvasive CyPath® Lung and AI-Built Algorithm
Yahoo Finance ·
- bioAffinity Technologies Reports Over 100% Growth in CyPath® Lung Sales Through Third Quarter 2026
Yahoo Finance ·
bioAffinity Technologies, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $6.2M | $9.4M | $2.5M | $4,803 |
| Net income | -$14.9M | -$9.0M | -$7.9M | -$8.2M |
| Diluted EPS | $-8.66 | $-22.50 | $-0.91 | $-1.81 |
| Total assets (year end) | $11.0M | $6.5M | $8.2M | $12.2M |
| Cash and equivalents (year end) | $6.4M | $1.1M | $2.8M | $11.4M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About bioAffinity Technologies, Inc.
- Ticker
- BIAF (Nasdaq)
- Industry
- Services-Commercial Physical & Biological Research
- Headquarters
- San Antonio, TX
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1712762
- Former names
- bioAffinity Technologies, Inc.
Frequently asked questions
What exchange is bioAffinity Technologies, Inc. listed on?
bioAffinity Technologies, Inc. trades on the Nasdaq under the ticker symbol BIAF.
What industry is bioAffinity Technologies, Inc. in?
bioAffinity Technologies, Inc. is classified by the SEC under "Services-Commercial Physical & Biological Research", part of the Healthcare sector on StockTweeting.
Where is bioAffinity Technologies, Inc. headquartered?
bioAffinity Technologies, Inc.'s business address on file with the SEC is in San Antonio, TX.
When does bioAffinity Technologies, Inc.'s fiscal year end?
bioAffinity Technologies, Inc.'s fiscal year ends on December 31.
How much revenue did bioAffinity Technologies, Inc. report?
bioAffinity Technologies, Inc. reported $6.2M in revenue for calendar year 2025, according to its SEC filings.